Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally... Show more
Alvotech (ALVO) is a global biotechnology company that develops and manufactures biosimilar medicines — lower-cost, highly similar versions of already-approved biologic drugs. Biosimilars aim to expand patient access and reduce healthcare spending by offering clinically comparable alternatives to expensive branded biologic therapies. Investors follow Alvotech for its exposure to the growing biosimilars market and its partnerships that reach patients across the United States, Europe, Japan, China, and other regions.
Alvotech was founded in 2013 by Robert Wessman, an experienced pharmaceutical entrepreneur who previously built the generic drug company Alvogen and led Actavis Group. The company is headquartered in Reykjavik, Iceland, where its main research, development, and manufacturing site is located. Alvotech completed its business combination with Oaktree Acquisition Corp II on June 15, 2022, and began trading on the Nasdaq the following day. It is also listed on the Nasdaq Iceland exchange, with additional depository receipts traded in Sweden.
The company's business model is built around the development and manufacture of biosimilars, which are biologic medicines designed to be highly similar to reference products whose patents have expired or are nearing expiration. Unlike traditional generic drugs, biosimilars are complex biologic therapies that require extensive clinical testing and specialized manufacturing. Alvotech pursues a fully integrated approach, handling development, regulatory filing, and manufacturing in-house while partnering with established pharmaceutical companies for commercialization.
Alvotech's primary revenue sources include product sales and service revenue, as well as license and other revenue generated through its commercial partnerships. The company has five biosimilars approved and marketed in multiple global markets, including biosimilars to Humira (adalimumab), Stelara (ustekinumab), Simponi (golimumab), Eylea (aflibercept), and Prolia/Xgeva (denosumab). These products address autoimmune disorders, eye disorders, and bone disorders, among other therapeutic areas. Its disclosed pipeline includes additional candidates targeting autoimmune conditions, osteoporosis, respiratory disease, and cancer.
A central element of Alvotech's market position is its strategic partnership with Teva Pharmaceutical Industries (TEVA), which holds exclusive U.S. commercialization rights to Alvotech's Humira biosimilar. Alvotech has also formed a broad network of regional partners across Europe, Asia, Latin America, Africa, and the Middle East to extend its global reach.
Investors pay attention to ALVO because of the long-term growth opportunity in the biosimilars market. As blockbuster biologic drugs lose patent exclusivity, biosimilars can capture meaningful market share by offering lower-cost alternatives. Alvotech's integrated manufacturing capability and its portfolio of products referencing some of the world's highest-revenue biologics position it to benefit from this trend.
The company's competitive positioning is reinforced by its ability to develop high-concentration, interchangeable formulations — such as its high-concentration, citrate-free Humira biosimilar, which was approved by the U.S. Food and Drug Administration as an interchangeable product in February 2024. Interchangeable status allows a biosimilar to be substituted for the reference product at the pharmacy level, a distinction that can support broader adoption. Alvotech's partnerships with established distributors also provide access to established commercial infrastructure without requiring the company to build its own global sales force.
Investing in ALVO carries several risks. The biosimilars industry is highly competitive, with multiple companies vying for the same reference-product markets, which can pressure pricing and market share. Alvotech's financial profile has historically included operating losses and significant research and development spending, reflecting the costly, time-intensive nature of biologic drug development and manufacturing. Regulatory approval timelines and outcomes are uncertain, and patent litigation with originator companies can delay or complicate product launches.
The company also relies heavily on commercial partners such as Teva, meaning its revenue can depend on partners' execution and strategic priorities. Finally, as a company with operations and listings across multiple jurisdictions, Alvotech is exposed to currency fluctuations, macroeconomic conditions, and regulatory differences in the various markets it serves.
Tickeron's AI Screener is an AI-powered stock and ETF discovery platform that helps traders and investors identify opportunities using technical indicators, fundamentals, volatility, trends, AI-generated signals, industries, price patterns, and customizable filters. Users can efficiently screen thousands of stocks and ETFs to surface ideas that match their own investment strategies, from momentum and value to income and sector rotation. Explore the AI Screener to discover opportunities aligned with your approach.
Alvotech (ALVO) stands out as a dedicated biosimilar developer and manufacturer with a growing portfolio of approved products and a broad pipeline. Its integrated capabilities and global partnership model make it a notable participant in the expanding biosimilars market, while its ongoing reliance on partners and the competitive nature of the industry remain important considerations for investors evaluating the company's long-term outlook.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Industry PharmaceuticalsGeneric